Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1

Interventions

Cyclophosphamide 14fludarabine phosphate 11Cyclosporine 11Antilymphocyte Serum 10Mycophenolic Acid 9ruxolitinib 8Radiotherapy 6Cord Blood Stem Cell Transplantation 6Busulfan 6fludarabine 5Whole-Body Irradiation 5Tacrolimus 5Methylprednisolone 5Azacitidine 5Stem Cell Transplantation 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4Melphalan 4Filgrastim 4thymoglobulin 3parsaclisib 3Sirolimus 3Nivolumab 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3abiraterone 2Tretinoin 2Surveys and Questionnaires 2Sunitinib 2Rituximab 2Moxifloxacin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Primary Myelofibrosis × Liposomes × Clear all
NCT03878199 2026-04-24

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Ohio State University Comprehensive Cancer Center

Phase 1/2 Terminated
12 enrolled 15 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡